BioInnovation Institute expands support for portfolio startups
BioInnovation Institute (BII), a life science accelerator established by the Novo Nordisk Foundation, has announced an additional €1.3 million in follow-on funding for five of its portfolio companies. The new capital is aimed at helping early-stage ventures advance critical biotech, healthtech and life science innovation from lab research toward clinical validation and commercialization.
Follow-on funding to bridge the early-stage gap
The fresh €1.3 million allocation is designed as follow-on support for startups that have already completed key milestones within BII’s programs. By extending funding beyond the initial grant phase, BioInnovation Institute seeks to close the notorious early-stage financing gap that often stalls promising therapeutics, diagnostics and medtech projects before they reach investors or industry partners.
According to BII, the five selected portfolio companies demonstrated strong scientific foundations, scalable business models and clear clinical or societal impact. The additional backing will typically be used to expand research teams, generate regulatory-grade data, strengthen intellectual property positions and prepare for larger venture capital rounds.
Strategic role of the Novo Nordisk Foundation
As a Novo Nordisk Foundation initiative, BioInnovation Institute plays a strategic role in nurturing Nordic and European life science ecosystems. The foundation’s long-term commitment enables BII to offer not only non-dilutive funding, but also access to specialist mentoring, shared lab facilities and a global network of industry experts and investors.
BII’s follow-on scheme is positioned as a catalyst for translating academic breakthroughs into viable health solutions, from novel biotherapeutics to next-generation digital health tools. By reinforcing five emerging companies with targeted capital at a critical stage, the institute aims to accelerate the path from scientific discovery to patient and societal benefit.
Strengthening Europe’s life science pipeline
The new €1.3 million package underlines growing recognition that sustained, staged funding is essential for deep-tech and life science ventures. With this move, BioInnovation Institute signals its intent to remain a key anchor for high-potential startups working on solutions to pressing global health and sustainability challenges.